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Abstract
Introduction: Previous studies of long-term treatment response in fibromyalgia and other chronic pain states have
generally been limited to approximately one year, leaving questions about the longer-term durability of response.
The purpose of this study was to demonstrate continuing efficacy of milnacipran by characterizing changes in pain
and other fibromyalgia symptoms after discontinuing long-term treatment. The mean length of milnacipran
treatment at the time of randomized withdrawal was 36.1 months from initial exposure to milnacipran
(range, 17.9 to 54.4 months).
Methods: After completing a long-term, open-label, lead-in study of milnacipran (which followed varying periods
of exposure in previous studies), adult patients with fibromyalgia entered the four-week open-label period of the
current study for evaluation of ongoing treatment response. After the four-week period to confirm new baseline
status, 151 patients taking milnacipran ≥100 mg/day and reporting ≥50% improvement from pre-milnacipran
exposure in Visual Analogue Scale (VAS) pain scores were classified as responders. These responders entered the
12-week, double-blind withdrawal period in which they were randomized 2:1 to continue milnacipran or switched
to placebo. The prespecified primary parameter was loss of therapeutic response (LTR), defined as increase in VAS
pain score to <30% reduction from pre-milnacipran exposure or worsening of fibromyalgia requiring alternative
treatment. Adverse events and vital signs were also monitored.
Results: Time to LTR was shorter in patients randomized to placebo than in patients continuing milnacipran
(P < 0.001). Median time to LTR was 56 days with placebo and was not calculable for milnacipran, because less
than half of the latter group of patients lost therapeutic response by study end. Additionally, 81% of patients
continuing on milnacipran maintained clinically meaningful pain response (≥30% improvement from pre-
milnacipran exposure), compared with 58% of patients switched to placebo (sensitivity analysis II; P < 0.001). The
incidences of treatment-emergent adverse events were 58% and 47% for placebo and milnacipran, respectively.
Mean decreases in blood pressure and heart rate were found in both groups, with greater decreases for patients
switched to placebo.
Conclusions: Continuing efficacy of milnacipran was demonstrated by the loss of effect following withdrawal of
treatment in patients who received an average of three years of milnacipran treatment.
Trial registration: ClinicalTrials.gov: NCT01014585
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Introduction
Fibromyalgia is a complex disorder characterized by
chronic widespread pain, fatigue, stiffness, poor sleep,
depressed mood and cognitive difficulties [1-3]. On the
basis of the 1990 American College of Rheumatology
(ACR) classification criteria, which focus on pain and
tenderness [4], it has been estimated that fibromyalgia
affects 2% to 4% of the general population [5,6]. How-
ever, in a recent population-based study that used modi-
fied ACR 2010 diagnostic criteria [7], which incorporate
many of the other hallmark symptoms of fibromyalgia
[8], the estimated prevalence was 6.4%. Because ongoing
therapy is often required to manage the chronic symp-
toms of fibromyalgia, demonstration of a medicine’s
long-term efficacy is of great interest to both clinicians
and patients.
Centrally acting analgesics, such as the tricyclic com-
pounds, were investigated once it became clear that the
diffuse pain and other symptoms of fibromyalgia were
likely due to aberrations in the central nervous system.
Preliminary studies with amitriptyline and cyclobenzapr-
ine showed efficacy in patients receiving one to three
months of treatment [9,10]. These initially promising
results were not replicated in subsequent longer-term
studies, and tolerability is always an issue when using
tricyclic compounds. Tramadol, another centrally acting
analgesic that likely acts by largely augmenting seroto-
nergic and noradrenergic activity (along with some weak
μ-opioid effects) has also been shown to have short-
term efficacy in patients with fibromyalgia [11-13].
As the pathophysiology of fibromyalgia became better
understood, research focused on other centrally acting
analgesics that would likely improve this condition [14].
This led to the approval of three medications by the US
Food and Drug Administration (FDA) for the manage-
ment of fibromyalgia: pregabalin, duloxetine and milna-
cipran. FDA approval of these drugs was based on
results from large, randomized, placebo-controlled trials
ranging from three to six months in duration [15-17]. In
addition to each compound demonstrating efficacy in at
least two of these pivotal trials, all three compounds
were evaluated in extension studies that ranged from
three months to one year in duration [18-21]. The long-
est fibromyalgia study to date was an open-label trial in
which patients received up to 3.25 years of milnacipran
after having participated in prior placebo-controlled
trials or extension studies [22].
Although treatment benefits were found in the exten-
sion studies and the open-label milnacipran study, none
included a placebo control group, because placebo-
controlled, parallel-group clinical trials are ethically and
practically difficult to conduct over long periods of time
in patients with chronic pain. Therefore, this randomized
withdrawal study was conducted to investigate the effects
of discontinuing treatment of fibromyalgia patients who
had completed participation in the long-term, open-label
milnacipran study [22]. This design provided the oppor-
tunity to use a randomized, double-blind, placebo-
controlled method to evaluate the long-term efficacy of
milnacipran in patients with fibromyalgia.
Materials and methods
Design overview
Enrollment began on 20 November 2009, and the last
patient visit was completed on 7 June 2010. The study
was conducted at 58 US centers and approved by the
institutional review board or ethics committee at each
site (Appendix 1, Additional File 1), and complied with
Good Clinical Practice guidelines and the Declaration of
Helsinki. All patients provided their written informed
consent to participate in the study.
Participants
Eligible patients were adults meeting the 1990 ACR
criteria for fibromyalgia [4] who entered directly from a
long-term, open-label, flexible-dose, lead-in study in which
they received milnacipran 50 mg/day to 200 mg/day for up
to 3.25 years [22]. Prior to this lead-in study, patients had
received up to 15 months of treatment with milnacipran
100 mg/day or 200 mg/day during double-blind studies
[20,21,23-27], resulting in up to 4.5 years of milnacipran
exposure prior to entering into the current discontinua-
tion study.
Key exclusion criteria included significant risk of sui-
cide, history of serious psychiatric disorder, substantial
alcohol use or abuse, pregnancy or breastfeeding, cardio-
vascular disease within the past 12 months, mean systo-
lic blood pressure >180 mmHg or diastolic blood
pressure >110 mm Hg, uncontrolled narrow-angle glau-
coma, active liver disease, severe renal impairment and
any other medical disorder that might preclude partici-
pation as judged by the principal investigator. Certain
pharmacologic agents were prohibited during the study,
including monoamine oxidase inhibitors, stimulant med-
ications, anorectic agents, daily opiates, sodium oxybate
and anesthetic and/or opiate patches. Although daily
opiates were prohibited, intermittent use was allowed as
needed, except during the seven days before scheduled
study visits.
Randomization and interventions
The study included four weeks during which the
patients receiving the same milnacipran dosage as in the
lead-in study (25 mg to 100 mg twice daily), twelve
weeks with patients randomized to milnacipran or pla-
cebo (double-blind) and one week of tapering (double-
blind). After the four-week open-label period, patients
receiving a minimum dosage of milnacipran 100 mg/day
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and achieving ≥50% pain improvement from pre-milnaci-
pran exposure (that is, baseline Visual Analogue Scale
(VAS) pain score prior to any milnacipran treatment in
any study) were classified as responders and randomized
(2:1) to continue milnacipran at the same dosage or were
switched to placebo. Pain improvement was assessed
using 24-hour recall VAS pain scores (range, 0 = “no
pain” to 100 = “worst possible pain”). The 50% threshold
was not selected as a benchmark for clinically meaningful
pain reduction, but rather to enrich the population of
responders so that loss of response after randomization
(that is, <30% pain reduction from pre-milnacipran expo-
sure and/or worsening of fibromyalgia requiring alterna-
tive treatment) could be measured. Patients not meeting
the protocol-defined responder criteria were also rando-
mized and followed in the study. However, because these
patients were not the primary focus of the study, their
results are not presented in this report.
Randomization codes were generated and securely
stored by Forest Research Institute, Inc (Jersey City, NJ,
USA). An interactive voice and/or web response system
was used to calculate the mean pain intensity score dur-
ing the last week of the open-label period, to allocate
patients to the appropriate responder or nonresponder
population and to dispense investigational medications,
which were sealed and coded to maintain the double-
blinding.
Assessments
The primary efficacy parameter was time to loss of ther-
apeutic response (LTR), defined as time from baseline
(randomization) to the first double-blind study visit in
which a patient had <30% reduction in VAS pain from
pre-milnacipran exposure or worsening of fibromyalgia
requiring alternative treatment, as judged by the study’s
principal investigator. The 30% threshold was based on
an accepted definition of clinically meaningful pain
reduction [28]. Patients completed 24-hour recall VAS
pain assessments for seven days before each study visit.
Pain intensity was calculated as the weekly average of
daily assessments. Three sensitivity analyses were per-
formed to confirm findings from the primary analysis
using the following LTR definitions: (1) <30% reduction
in VAS pain score from pre-milnacipran exposure or
withdrawal from the study for any reason, (2) <30%
reduction in VAS pain score from pre-milnacipran
exposure and (3) worsening of fibromyalgia requiring
alternative treatment. The second sensitivity analysis
was used to determine the percentage of patients who
maintained clinically meaningful pain improvements
from pre-milnacipran exposure (≥30% reduction in VAS
pain score).
Secondary efficacy parameters included time to wor-
sening based on the Patient Global Impression of
Change (PGIC) and the Multidimensional Assessment
of Fatigue (MAF) global fatigue index [29]. Based on a
seven-point scale, worsening in PGIC was defined as
patients’ reporting their overall change in fibromyalgia
from randomization as “much worse” or “very much
worse” (score 6 or 7). Worsening in MAF was defined
as a 10-point increase from randomization in the fatigue
global index score (1 = “no fatigue” to 50 = “severe
fatigue”).
Additional efficacy parameters included time to wor-
sening in Short Form-36 Health Survey (SF-36) Physical
Component Summary (PCS) and Mental Component
Summary (MCS) scores [30], with worsening defined as
a six-point decrease from randomization. Mean score
changes from randomization in VAS pain, Brief Pain
Inventory (BPI) [31], Revised Fibromyalgia Impact Ques-
tionnaire (FIQR) [32], SF-36 PCS and MCS, and Multi-
ple Ability Self-Report Questionnaire (MASQ) [33] were
also analyzed.
Adverse events, vital signs and clinical laboratory tests
were monitored for safety. Treatment emergent adverse
events were defined as adverse events that occurred
after the first dose of double-blind treatment or increase
in severity during this period. Efficacy and safety assess-
ments were conducted at all study visits with the excep-
tion of PGIC, which was assessed at weeks 2, 4, 8 and
12 of the double-blind period.
Statistical analyses
Assuming that 60% of the placebo and 35% of the mil-
nacipran groups would experience LTR by end of the
double-blind period, it was estimated that 180 enrolled
patients (placebo = 60 and milnacipran = 120) would be
needed to detect a 25% difference between treatment
groups with 90% power at the two-sided 5% significance
test. The safety population included all randomized
patients who received one or more doses of double-
blind treatment. The intent-to-treat population included
patients in the safety population who had one or more
postrandomization pain assessments. Kaplan-Meier esti-
mates were used to analyze time to LTR and time to
worsening based on PGIC, MAF, SF-36 PCS and SF-36
MCS scores, with comparisons between treatment
groups analyzed using the logrank test. Hazard ratios
(HRs) with 95% confidence intervals (95% CIs) were cal-
culated using a Cox proportional hazards model with
treatment group as the explanatory variable. Patients
who completed the study without experiencing LTR or
who withdrew for any reason other than LTR were cen-
sored in the primary efficacy analyses.
An analysis of covariance model was used to calculate
mean changes from randomization, with treatment
group and study center as factors and baseline value as
a covariate. Missing data were imputed using the last
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observation carried forward approach. Tests were
two-sided performed at the 5% level of significance.
Descriptive statistics were used to analyze changes from
randomization in vital signs and clinical laboratory
values, with the end of the study defined as the last
available assessment in the double-blind period. All ana-
lyses were performed using SAS version 9.1.3 software
(SAS Institute, Cary, NC, USA).
Results
Patients
Of the 340 patients who completed the four-week open-
label period, 151 (44.4%) were classified as responders
and randomized to continue milnacipran (n = 100) or
switched to placebo (n = 51) (Figure 1). Of the patients
randomized to continue milnacipran, 75 patients (75.0%)
completed the study and 31 patients (60.8%) randomized
to placebo completed the study. Most discontinuations
during the double-blind period were due to worsening
of fibromyalgia requiring alternative treatment, which
was one of the LTR definitions used in this study. Two
patients randomized to milnacipran discontinued due to
an adverse event. One patient randomized to placebo
did not receive double-blind treatment and was there-
fore excluded from safety and efficacy analyses.
Among the 150 patients analyzed for safety and effi-
cacy, demographics and clinical characteristics were
similar between treatment groups at randomization
(Table 1). In these patients, mean total exposure prior
to randomization (that is, total duration of milnacipran
treatment in all prior studies and the four-week open-
label period of this study) was 36.1 months (range, 17.9
to 54.4 months). Total duration of milnacipran exposure
prior to randomization was as follows (percentage of
patients): more than 12 to 24 months (14%), more than
24 to 36 months (39%), more than 36 to 48 months
(33%) and more than 48 to 60 months (14%).
Efficacy parameters
Patients discontinuing milnacipran had significantly
shorter time to LTR than patients who continued treat-
ment (primary analysis; HR, 0.44 [95% CI, 0.27 to 0.71];
P < 0.001) (Figure 2 and Table 2). Median time to LTR
was 56 days for placebo and was not calculable for mil-
nacipran, because 50% of patients in the latter group did
not experience LTR by the end of the study. At the end
of the study, 64% of the patients switched to placebo
experienced an LTR compared with 35% of patients
who continued milnacipran. Very similar results were
found when LTR was defined as more than 30% reduc-
tion in VAS pain score from pre-milnacipran exposure
or withdrawal from the study for any reason (instead of
worsening of fibromyalgia requiring alternative treat-
ment) (sensitivity analysis I; HR, 0.46 [95% CI, 0.29 to
0.74]; P = 0.001). In addition, the percentage of patients
maintaining 30% or more pain improvement from pre-
milnacipran exposure was 81% in the milnacipran group
and 58% in the placebo group (sensitivity analysis II;
HR, 0.35 [95% CI, 0.19 to 0.65]; P < 0.001). The only
nonsignificant finding was for sensitivity analysis III,
which simply defined LTR as worsening of fibromyalgia
requiring alternative treatment.
Patients discontinuing milnacipran had a shorter time
to worsening than patients continuing treatment in
PGIC, MAF global fatigue, SF-36 PCS and SF-36 MCS
scores (Table 2), with significant between-group differ-
ences for PGIC (HR, 0.36 [95% CI, 0.20 to 0.63]; P <
0.001). In addition, mean least squares changes from
randomization indicated greater worsening in VAS pain,
BPI average pain, FIQR and SF-36 PCS scores with pla-
cebo versus milnacipran, with significant between-group
differences observed at all study visits (P < 0.05) (Figure
3). Patients switched to placebo also had greater wor-
sening from randomization in mental functioning (SF-36
MCS: placebo, -4.64; milnacipran, -2.79) and cognitive
difficulties (MASQ total: placebo, +3.43; milnacipran,
+2.45), although differences between treatment groups
were not significant.
Tolerability and safety outcomes
Among the 357 patients receiving milnacipran during the
four-week open-label period, treatment emergent adverse
events occurring in ≥2.5% of patients were upper respira-
tory tract infection (3.4%), nasopharyngitis (2.5%) and
nausea (2.5%). No serious adverse events occurred during
this period, and two patients discontinued due to adverse
events (one with nausea and one with hypertension).
During the double-blind period, 47% of patients continu-
ing milnacipran and 58% of patients switched to placebo
reported one or more treatment emergent adverse events
(Table 3). Adverse events led to premature discontinua-
tion in two patients receiving milnacipran (one with nau-
sea and vomiting and one with increased heart rate and
hypertension) and no patients receiving placebo. The
only serious adverse event (noncardiac chest pain) was
reported in one milnacipran-treated patient. No deaths
occurred during the study.
Mean decreases in sitting vital signs were found in
both treatment groups during the double-blind period,
with greater decreases observed in patients receiving
placebo. Mean changes from randomization to the end
of the study were as follows: systolic blood pressure
(placebo, -1.3 mmHg; milnacipran, -0.7 mmHg), diastolic
blood pressure (placebo, -3.4 mmHg; milnacipran, -0.8
mmHg) and pulse (placebo, -10.6 beats/min; milnaci-
pran, -2.7 beats/min). Potentially clinically significant
changes in vital signs were found in one patient receiving
milnacipran (heart rate, ≥120 beats/min with increase
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≥20 beats/min from randomization) and one patient
receiving placebo (heart rate, ≤50 beats/min with
decrease of ≥15 beats/min from randomization). No
potentially clinically significant change in laboratory
parameters occurred in more than two patients in either
treatment group.
Discussion
Because it can be difficult to conduct long-term, placebo-
controlled, parallel-arm studies to assess the efficacy of
chronic pain medications, we used a randomized, placebo-
controlled, withdrawal design in this trial to evaluate the
loss of therapeutic response in patients with fibromyalgia
who discontinued long-term treatment with milnacipran.
As in other withdrawal studies [34], including the Future
Revascularization Evaluation in patients with Diabetes
Mellitus: Optimal Management of Multivessel Disease
(FREEDOM) study of pregabalin in fibromyalgia [35],
the present study focused on a subset of patients who





































Did not meet entry criteria  4
Adverse event  2
Withdrawal of consent  7
Lost to follow-up  3
Other reasons  1
Discontinued 1
Did not meet entry criteria  1
Figure 1 Study flow. Responders were defined as patients who received a minimum dosage of milnacipran 100 mg/day and achieved ≥50%
pain improvement after long-term treatment. aPatients not meeting responder criteria were analyzed separately, but the results for these
patients are not presented in the current report. “Nonresponder” does not necessarily imply no improvement. bWorsening of fibromyalgia
requiring alternative treatment, which was one of the loss of therapeutic response (LTR) criteria used for the primary efficacy analysis and for
sensitivity analysis III. cPatients reaching the final study visit. dOne patient who did not receive at least one dose of the study drug was excluded
from safety and efficacy analyses. OL = open-label.
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Table 1 Patient demographics and baseline characteristicsa






Mean age (SD), years 54.0 (8.3) 54.5 (9.3) 54.3 (9.0)
Women, n (%) 48 (96.0) 96 (96.0) 144 (96.0)
Race, n (%)
White 47 (94.0) 96 (96.0) 143 (95.3)
Nonwhite 3 (6.0) 4 (4.0) 7 (4.7)
Mean weight (SD), kg 77.3 (16.7) 80.2 (14.5) 79.2 (15.3)
Mean body mass index (SD), kg/m2 29.0 (6.1) 29.7 (5.2) 29.5 (5.5)
Mean SF-36 PCS score (SD) 41.3 (10.2) 41.6 (8.4) 41.5 (9.0)
Mean SF-36 MCS score (SD) 53.6 (11.3) 53.6 (9.0) 53.6 (9.8)
Mean FIQR total score (SD), range 0 to 100 21.4 (15.8) 19.4 (11.9) 20.1 (13.3)
Mean MAF global fatigue score (SD), range 1 to 50 21.4 (10.4) 20.7 (9.7) 21.0 (9.9)
Mean BPI average pain score (SD), range 0 to 10 2.5 (1.3) 2.3 (1.4) 2.3 (1.4)
Mean VAS pain score (SD), range 0 to 100 19.3 (11.6) 16.6 (9.6) 17.5 (10.3)
Mean VAS pain score (SD), pre-milnacipran exposureb 66.2 (14.7) 65.4 (13.0) 65.7 (13.6)
aBaseline is defined as the randomization visit in this study. BPI = Brief Pain Inventory; FIQR = Revised Fibromyalgia Impact Questionnaire; MAF =
Multidimensional Assessment of Fatigue; MCS = Mental Component Summary; PCS = Physical Component Summary; SF-36 = Short Form-36 Health Survey; VAS =
Visual Analogue Scale. bBaseline value from lead-in study prior to first milnacipran exposure.
Primary Event Time (Days)


























Figure 2 Kaplan-Meier plot of time to loss of therapeutic response. Loss of therapeutic response was defined as <30% reduction in Visual
Analogue Scale pain score from pre-milnacipran exposure or a worsening of fibromyalgia requiring an alternative treatment. Circles represent
censored patients.
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design between the present study and FREEDOM, and
though it would be improper to make any formal compari-
son between the two studies, it is of interest that both
showed a loss of response in almost two-thirds of patients
who were taken off therapy. It is also true that both studies
showed a loss of response in almost one-third of patients
continuing on therapy-attesting, perhaps, to the underly-
ing variability in the pain of fibromyalgia. The fact that
approximately one-third of patients switched to placebo in
each study did not lose their therapeutic response is also
of interest. Again, this may reflect the natural variability in
the disease; in either case, there is sufficient evidence to
suggest that these medications had a pharmacologic effect
on the fundamental disturbances in pain processing that
are characteristic of fibromyalgia [36].
In the current study, we analyzed data from patients
who achieved ≥50% pain improvement after receiving
1.5 to 4.5 years (mean, 3 years) of milnacipran treatment
in one or more prior clinical trials. Milnacipran dosages
had been optimized for each patient entering the with-
drawal study (50 mg/day to 200 mg/day), although the
present analyses were limited to patients receiving at
least the minimum recommended dosage of 100 mg/day
[17]. The results of these analyses indicate that the
patients classified as responders had experienced clinical
benefits during long-term treatment with milnacipran,
as evidenced by a shorter time to LTR and greater wor-
sening in symptom severity postrandomization among
the patients who were switched to placebo (that is, dis-
continued treatment) as compared to those who contin-
ued milnacipran. For the prespecified primary endpoint,
significantly more patients in the placebo group experi-
enced an LTR by the end of study compared to the mil-
nacipran group (64% vs. 35%, P < 0.001).
The primary endpoint, as well as two of the three sen-
sitivity analyses, included either worsening of fibromyal-
gia or discontinuation from the study as a definition of
LTR. Sensitivity analysis II, however, was based solely
on the pain criterion (that is, <30% reduction in VAS
pain score from pre-milnacipran exposure). The results
of this analysis, in conjunction with analyses of mean
pain scores at various time points (that is, pre-milnaci-
pran exposure, study randomization and end of study),
may provide some important insights about pain
responses in patients who had received up to 4.5 years
of prior milnacipran treatment. First, notable pain
improvements were found in patients who received
long-term milnacipran treatment, as indicated by the
73% decrease in mean VAS pain score from pre-milnaci-
pran exposure (65.7%) to randomization (17.5%) (Table
1). Of course, this result was derived from a selected
group of responders who elected to continue treatment
Table 2 Time to loss of therapeutic responsea
Measurement Treatment group, n Time to LTR, days (95% CI)b Hazard ratio
(95% CI)c
P-valued Patients with LTR at
end of DB
treatment, n (%)
25th percentile 50th percentile
Primary analysis PBO, 50 18 (16 to 29) 56 (28 to 85) 0.44 (0.27 to 0.71) <0.001 32 (64)
MLN, 100 45 (29 to 59) NC 35 (35)
Sensitivity analysis I PBO, 50 18 (16 to 29) 56 (28 to 85) 0.46 (0.29 to 0.74) 0.001 32 (64)
MLN, 100 36 (29 to 57) NC 37 (37)
Sensitivity analysis II PBO, 50 28 (18 to 63) 85 (60 to NL) 0.35 (0.19 to 0.65) <0.001 21 (42)
MLN, 100 NC NC 19 (19)
Sensitivity analysis III PBO, 50 29 (17 to NL) NC 0.59 (0.32 to 1.08) 0.08 18 (36)
MLN, 100 86 (43 to NL) NC 24 (24)
PGIC PBO, 50 22 (15 to 31) 86 (30 to NL) 0.36 (0.20 to 0.63) <0.001 25 (50)
MLN, 100 NC NC 22 (22)
MAF global fatigue PBO, 50 18 (16 to 68) NC 0.80 (0.46 to 1.38) 0.41 20 (40)
MLN, 100 30 (26 to 59) NC 36 (36)
SF-36 PCS PBO, 50 15 (15 to 22) 68 (18 to NL) 0.81 (0.50 to 1.30) 0.36 26 (52)
MLN, 100 23 (15 to 33) 87 (57 to NL) 47 (47)
SF-36 MCS PBO, 50 28 (16 to 46) 57 (29 to NL) 0.74 (0.44 to 1.24) 0.24 23 (46)
MLN, 100 29 (23 to 60) 90 (85 to NL) 40 (40)
aLoss of therapeutic response was defined as follows: (1) primary analysis: <30% reduction in Visual Analogue Scale (VAS) pain score from pre-milnacipran
exposure or worsening of fibromyalgia requiring alternative treatment; (2) sensitivity analysis I: <30% reduction in VAS pain score from pre-milnacipran exposure
or withdrawal from the study for any reason; (3) sensitivity analysis II: <30% reduction in VAS pain score from pre-milnacipran exposure; or (4) sensitivity analysis
III: worsening of fibromyalgia requiring alternative treatment. DB = double-blind; LTR = loss of therapeutic response; MAF = Multidimensional Assessment of
Fatigue; MCS = Mental Component Summary; MLN = milnacipran; NC = not calculable (no patients in quartile); NL = no limit; PBO = placebo; PCS = Physical
Component Summary; PGIC = Patient Global Impression of Change; SF-36 = Short Form-36 Health Survey. bQuartiles (that is, 25th percentile, 50th percentile)
based on Kaplan-Meier estimates. cHazard ratio of milnacipran versus placebo based on Cox proportional hazards regression model with treatment group as an
explanatory variable. dP-values based on logrank comparison between milnacipran and placebo.
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for an extended period of time, and the large mean
decrease in pain does not necessarily imply that long-
term treatment increases response to milnacipran.
Nonetheless, the results from sensitivity analysis II indi-
cate that, after randomization, the percentage of patients
maintaining clinically meaningful pain improvement
(that is, >30% decrease in pain from pre-milnacipran
exposure) was higher in the group continuing milnaci-
pran (81%) than in the group switched to placebo (58%)
(Table 2). Although mean increases in VAS and BPI
pain scores from randomization to the end of the study
were observed in both treatment groups, worsening was
greater in patients who discontinued milnacipran. There
is no definitive explanation for the slight increase in
mean pain scores in patients continuing milnacipran,
but because randomization was based on achieving a
certain level of pain reduction (≥50%), it is likely that
some regression to the mean in pain severity occurred
in this group. It is also possible that the results reflect
some patients’ assumptions that they had been discon-
tinued from active treatment (for example, a “reverse
placebo” or nocebo effect) [37].
This study also demonstrated that improvements in
global status (PGIC), fibromyalgia severity (FIQR) and
physical functioning (SF-36 PCS) occurred in patients
receiving long-term milnacipran treatment. A higher
percentage of patients discontinuing milnacipran
reported feeling “much worse” or “very much worse”
since randomization as compared with patients who
continued treatment (50% vs. 22%, P < 0.001). These
findings were supported by mean worsening from ran-
domization in FIQR and SF-36 PCS scores, which were
significantly worse with placebo than milnacipran at
every study visit.
In patients who discontinued treatment, the greatest


















































































































































Figure 3 Least squares mean changes from baseline in additional efficacy outcomes. Least squares mean changes and standard errors
from randomization at weeks 2, 4, 8 and 12 of double-blind treatment (visits 4, 5, 6 and 7), with the last observation carried forward. BPI = Brief
Pain Inventory; FIQR = Revised Fibromyalgia Impact Questionnaire; LS = least squares; SF-36 = Short Form-36 Health Survey; VAS = Visual
Analogue Scale. *P < 0.05; **P < 0.01; ***P < 0.001 versus placebo.
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randomization and week 2, whereas mean VAS pain
scores worsened steadily from randomization to week 8
(Figure 3). These results are consistent with findings in
an earlier milnacipran study that included 12 weeks of
double-blind treatment followed by a 2-week placebo-
controlled discontinuation period [38]. The results from
the short discontinuation period in that study also seem
to indicate that physical functioning worsens more
rapidly than pain after withdrawal of treatment. The
reasons for these findings are unknown, but one possi-
ble explanation is that the function measures used in
previous milnacipran studies were more sensitive than
pain measures for detecting loss of response. It is also
possible that when fibromyalgia patients experience a
decline in physical function after discontinuing treat-
ment, they decrease their activity levels, which in turn
prevents them from experiencing increased pain sever-
ity. Alternatively, the results may simply indicate that
the effects of milnacipran on pain are more persistent
than its effects on functioning.
In addition to demonstrating the continuing efficacy of
milnacipran, the worsening of pain and other symptoms
observed in this withdrawal study confirms the benefit of
ongoing treatment in patients with fibromyalgia. More-
over, these results suggest that the underlying pathophy-
siology of fibromyalgia was been reversed by long-term
treatment, which has important implications for our
understanding of this disorder-namely, that even a reason-
ably successful treatment, as demonstrated in this study
by the ≥50% pain improvement from pre-milnacipran
exposure at randomization, is not sufficient to “cure” indi-
viduals with this disorder by somehow resetting pain
processing. This finding, combined with the fact that
spontaneous remission is very uncommon, suggests that
individuals with fibromyalgia who experience significant
benefit with initial therapy (at least with this compound)
should expect to continue to require long-term treatment.
No unexpected safety issues were observed in this
study. Nausea and headache, the most commonly
reported treatment emergent adverse events with milna-
cipran in placebo-controlled trials [25,26,39] and the
long-term lead-in study [22], were each observed in 4%
of patients continuing milnacipran in this study. In
patients discontinuing treatment, the most common
treatment emergent adverse events were sinusitis, per-
ipheral edema and irritability (6% each with none rated
as severe). Of those symptoms, only irritability is com-
monly associated with the abrupt discontinuation of
serotonin and norepinephrine reuptake inhibitors
[16,17,40]. However, patients in this study were not spe-
cifically evaluated for a discontinuation syndrome. Mean
increases in blood pressure and heart rate have been
reported in milnacipran-treated patients during placebo-
controlled trials [17]. The results in the present study
suggest that the effects of milnacipran on blood pressure
and heart rate do not persist after patients discontinue
treatment.
A few limitations should be noted. First, on the basis
of the results reported above, no conclusions can be
drawn about the effects of discontinuing milnacipran in
patients who did not meet the stringent ≥50% pain
responder criterion. However, subsequent analyses of
this study indicate that patients who had 30% to <50%
pain improvement from pre-milnacipran exposure,
which indicates clinically meaningful improvement, also
experienced loss of therapeutic effect after milnacipran
was discontinued [41]. Second, although milnacipran
dosages were optimized for each patient entering this
withdrawal study (50 mg/day to 200 mg/day), the ana-
lyses were designed to evaluate only those patients who
received at least 100 mg/day, the recommended mini-
mum dosage [17]. Thus, no conclusions can be drawn
regarding the effects of any specific dosage. Third, as
has been discussed in other randomized withdrawal stu-
dies [34,35], some patients may have suspected that they
were on placebo if they experienced a clear worsening
of symptoms during the 12-week discontinuation period.
Any such unblinding effect may have influenced how
patients assessed their pain and other symptoms in this
study. Nonetheless, significant differences between mil-
nacipran and placebo were observed.
Conclusions
In patients who received milnacipran for an average of
three years (range, 1.5 to 4.5 years), loss of therapeutic
response upon discontinuation of treatment provides
Table 3 Incidence of treatment-emergent adverse eventsa




Patients with ≥1 TEAE 29 (58) 47 (47)
Nausea 1 (2) 4 (4)
Headache 0 4 (4)
Vomiting 1 (2) 4 (4)
Sinusitis 3 (6) 4 (4)
Upper respiratory tract infection 2 (4) 4 (4)
Fatigue 1 (2) 4 (4)
Pain in extremity 1 (2) 4 (4)
Fall 0 4 (4)
Arthralgia 1 (2) 3 (3)
Fibromyalgia 1 (2) 3 (3)
Peripheral edema 3 (6) 2 (2)
Hypothyroidism 2 (4) 1 (1)
Influenza 2 (4) 1 (1)
Irritability 3 (6) 0
Neck pain 2 (4) 0
aReported in ≥3% of patients in either treatment group during the double-
blind period. TEAE = treatment emergent adverse event.
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evidence of long-term efficacy of this medication for the
management of fibromyalgia.
Additional material
Additional file 1: List of Institutional Review Boards and Study
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